Business Context and Reporting Period
This Form 6-K filing covers the month of May 2012 for Prana Biotechnology Limited (ASX: PBT), a foreign private issuer. The document reports the results of a General Meeting held on May 18, 2012. Note: The request metadata references "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Shareholders voted on two key resolutions at the General Meeting. Both were carried unanimously on a show of hands. The detailed proxy voting results were as follows:
- Resolution 1: Approval of Prior Issue of new Securities
- For: 24,442,596
- Against: 1,501,700
- Abstain: 2,241,840
- Total Votes: 46,272,884
- Resolution 2: Replacement of Previous Shareholder Approval for Share Placement
- For: 24,185,646
- Against: 1,648,150
- Abstain: 2,352,340
- Total Votes: 46,272,884
The Chairman voted undirected proxies in his control in favor of all resolutions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves strictly as a disclosure of the meeting results required under Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001.
Investor Verification Checklist
- Verify the exact nature and terms of the "Prior Issue of new Securities" approved in Resolution 1.
- Confirm the details of the "Share Placement" referenced in Resolution 2 and the specific previous approval being replaced.
- Review the company's latest financial statements (Form 20-F) for actual revenue and liquidity data, as this filing contains none.
- Confirm the current corporate name and ticker symbol, noting the discrepancy between the request metadata (Alterity Therapeutics) and the filing (Prana Biotechnology).